Research graph
References from Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumors. Local targets link to admitted publications; unresolved targets remain external evidence.
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
10.1200/po.21.00372 · 2022 · External reference
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
10.3390/ijms231911529 · 2022 · External reference
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges.
10.1126/sciadv.abi8618 · 2022 · External reference
Circulating tumor DNA and liquid biopsy in oncology
10.1038/s43018-020-0043-5 · 2020 · External reference
Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort.
10.1016/j.clon.2020.09.001 · 2021 · External reference
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
10.1016/j.cllc.2021.08.008 · 2021 · External reference
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
10.1001/jamaoncol.2019.3616 · 2019 · External reference
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
10.1158/2159-8290.cd-17-0716 · 2017 · External reference
Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.
10.1200/cci.21.00031 · 2021 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
10.1158/1078-0432.ccr-16-3155 · 2017 · External reference
RECIST 1.1-Update and clarification: From the RECIST committee
10.1016/j.ejca.2016.03.081 · 2016 · External reference
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab
10.1002/1878-0261.13349 · 2023 · External reference
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
10.1158/2159-8290.cd-20-0047 · 2020 · External reference
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.
10.1001/jamaoncol.2019.0528 · 2019 · External reference
Circulating Tumor DNA Mutations in Progressive Gastrointestinal Stromal Tumors Identify Biomarkers of Treatment Resistance and Uncover Potential Therapeutic Strategies.
10.3389/fonc.2022.840843 · 2022 · External reference
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
10.1016/j.annonc.2022.02.007 · 2022 · External reference
Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors
10.1158/1535-7163.mct-19-1060 · 2020 · External reference
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
10.1016/j.annonc.2021.05.806 · 2021 · External reference
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
10.1038/s41587-021-00857-z · 2021 · External reference
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
10.1038/nm.3519 · 2014 · External reference
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
10.1158/2159-8290.cd-21-0634 · 2021 · External reference
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA.
10.1371/journal.pone.0140712 · 2015 · External reference
Clinical and analytical validation of foundation one liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin.
10.1371/journal.pone.0237802 · 2020 · External reference
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
10.1371/journal.pone.0264138 · 2022 · External reference
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
10.1038/nbt.2696 · 2013 · External reference
Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
2021 · External reference
Early Detection of Circulating Tumor DNA Postoperatively Enables Discovery of Resectable Metastatic Disease in a Patient with Colon Cancer.
10.1159/000520743 · 2021 · External reference
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
10.1186/s13073-017-0424-2 · 2017 · External reference
Abstract 1227: Somatic genome alterations in cancer as compared to inferred patient ancestry
10.1158/1538-7445.am2018-1227 · 2018 · External reference
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
10.1038/nature22364 · 2017 · External reference
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
10.1038/s41586-021-03642-9 · 2021 · External reference
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
10.1200/po.22.00261 · 2022 · External reference
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors.
2023 · External reference
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer
10.1158/1078-0432.ccr-23-1578 · 2023 · External reference
Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
10.1016/j.jmoldx.2023.09.004 · 2023 · External reference
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group
10.1093/clinchem/hvaa164 · 2020 · External reference
